Are women with polycystic ovarian syndrome at a high risk of nonalcoholic fatty liver disease; A meta-analysis

Hepatitis Monthly

Volumn 14, Issue 11, 2014, Pages

  Ramezani Binabaj, Mahdi ^a,b   Motalebi, Mohsen ^a   Karimi Sari, Hamidreza ^a   Rezaee Zavareh, Mohammad Saeid ^a,b   Alavian, Seyed Moayed ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Middle East Liver Diseases Research Center   (Iran)

Author keywords

Insulin resistance; Meta analysis; Metabolic syndrome; Non alcoholic fatty liver disease; Polycystic ovary syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; HUMAN; INSULIN RESISTANCE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PREVALENCE; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

EID: 84973889774     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.23235     Document Type: Review

References (39)

1. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Pe-termann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412–7.
2. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with poly-cystic ovary syndrome. Hum Reprod. 2010;25(1):212–20.
3. Saki F, Karamizadeh Z. Metabolic syndrome, insulin resistance and Fatty liver in obese Iranian children. Iran Red Crescent Med J. 2014;16(5).
4. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci. 2013;6(1):9–14.
5. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33(7):801–14.
6. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.
7. Lahsaee S, Ghazizade A, Yazdanpanah M, Enhesari A, Malekzadeh R. Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman. Gastro-enterol Hepatol Bed Bench. 2012;5(4):183–9.
8. Zuef LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341–7.
9. FAISAL A, GADALLAH AN, ZYITON A, ESKANDER A. Liver Afection in Polycystic Ovary Syndrome (PCOS).: ScholarlyEditions.
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–50.
11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vanden-broucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10).
12. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S7–8.
13. Zheng RH, Ding CF. Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. Zhonghua Fu Chan Ke Za Zhi. 2008;43(2):98–101.
14. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010;16(17):1941–51.
15. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5–10.
16. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–63.
17. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis. 2006;185(2):227–39.
18. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract. 2008;62(9):1337–43.
19. Rzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009;24(2):243–7.
20. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycys-tic ovary syndrome. J Endocrinol Invest. 2009;32(8):695–700.
21. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9(4):402–9.
22. Qu Z, Zhu Y, Jiang J, Shi Y, Chen Z. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med. 2013;11(9):725–32.
23. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496–501.
24. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J. 2004;147(1):106–12.
25. Orchard TJ, Temprosa M, Goldberg R, Hafner S, Ratner R, Marco-vina S, et al. The efect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–9.
26. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65(6 Pt 2):S57–63.
27. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–61.
28. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–42.
29. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fbrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004;41(6):943–9.
30. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006;30(1):13–7.
31. Diamanti-Kandarakis E, Christakou CD. Insulin Resistance in PCOS.: Springer; 2009.
32. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J Hepatol. 2014;6(4):199–206.
33. Awartani KA, Cheung AP. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can. 2002; 24(5):393–401.
34. Goessling W, Massaro JM, Vasan RS, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterol J. 2008;135(6):1935–44.
35. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686–92.
36. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalh-ori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008;14(18):2867–71.
37. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–50.
38. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis. 2001;21(1):71–80.
39. Jamali R. Non-Alcoholic Fatty Liver Disease.: Walter Siegenthaler; 2013.